The outlook of companies tied to Sildenafil's legacy presents a complex investment landscape. While the initial success generated substantial gains, generic competition have significantly impacted sales . Investing in related pharmaceutical firms now requires a careful assessment of patent protection , evolving healthcare trends , and the prospect